A detailed history of Strategic Blueprint, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Strategic Blueprint, LLC holds 16,496 shares of BMY stock, worth $886,824. This represents 0.05% of its overall portfolio holdings.

Number of Shares
16,496
Previous 17,293 4.61%
Holding current value
$886,824
Previous $937,000 26.89%
% of portfolio
0.05%
Previous 0.07%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 26, 2024

SELL
$40.25 - $52.99 $32,079 - $42,233
-797 Reduced 4.61%
16,496 $685,000
Q1 2024

Apr 23, 2024

BUY
$47.98 - $54.4 $363,592 - $412,243
7,578 Added 78.0%
17,293 $937,000
Q4 2023

Jan 25, 2024

BUY
$48.48 - $57.85 $207,252 - $247,308
4,275 Added 78.58%
9,715 $498,000
Q3 2023

Oct 18, 2023

BUY
$57.89 - $64.73 $24,950 - $27,898
431 Added 8.6%
5,440 $315,000
Q2 2023

Oct 18, 2023

BUY
$63.71 - $70.74 $10,066 - $11,176
158 Added 3.26%
5,009 $320,000
Q1 2023

Apr 28, 2023

BUY
$65.71 - $74.53 $36,994 - $41,960
563 Added 13.13%
4,851 $336,000
Q4 2022

Jan 26, 2023

BUY
$68.48 - $81.09 $47,456 - $56,195
693 Added 19.28%
4,288 $0
Q3 2022

Nov 08, 2022

BUY
$0.13 - $76.84 $19 - $11,449
149 Added 4.32%
3,595 $256,000
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $72,256 - $79,580
-995 Reduced 22.4%
3,446 $265,000
Q1 2022

Aug 12, 2022

SELL
$61.48 - $73.72 $799 - $958
-13 Reduced 0.29%
4,441 $324,000
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $155,312 - $181,057
-2,896 Reduced 39.4%
4,454 $277,000
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $182,006 - $213,197
3,076 Added 71.97%
7,350 $435,000
Q2 2021

Aug 12, 2021

BUY
$61.91 - $67.42 $264,603 - $288,153
4,274 New
4,274 $285,000
Q4 2019

Jan 10, 2020

SELL
$49.21 - $64.19 $4,379 - $5,712
-89 Closed
0 $0
Q3 2019

Oct 16, 2019

BUY
$42.77 - $50.71 $3,806 - $4,513
89 New
89 $5,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $114B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Strategic Blueprint, LLC Portfolio

Follow Strategic Blueprint, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strategic Blueprint, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Strategic Blueprint, LLC with notifications on news.